Publications
52
Citations
2,192
Est. group size
—
Recurring co-author estimate
Active years
22
Publishing since 2005
Cynthia Bodkin conducts clinical research in neurology, focusing on neuromuscular disorders such as amyotrophic lateral sclerosis (ALS), muscular dystrophies, and late-onset Pompe disease, as well as sleep disorders including REM sleep behavior disorder and restless legs syndrome. Much of the work involves clinical trials testing new drug therapies for these conditions. The research spans both the diagnosis and treatment of nerve, muscle, and sleep-related diseases.
Publication activity has been fairly steady over the last decade, averaging a few papers per year with a modest recent uptick in 2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Dilated Cardiomyopathy and Later Onset Limb-Girdle Muscular Dystrophy Associated With Fukutin and Lamin A/C Mutations
JACC Case Reports · 2026
- Reldesemtiv in Amyotrophic Lateral Sclerosis
JAMA Neurology · 2025
- Under-Recognition of Rapid Eye Movement Sleep Behavior Disorder in Younger Populations
Sleep Medicine Clinics · 2025
- Gender and Psychiatric Disparities in Rapid-Eye-Movement Sleep Behavior Disorder
Sleep Medicine Clinics · 2025
- 1422 High-Dose Rivastigmine in REM Behavior Disorder - A Therapeutic Coincidence or Stroke of Luck?
SLEEP · 2025
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
Journal of Neurology · 2024
- Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial
PLoS Medicine · 2024
- Parasomnias in Women
2023
- Parkinson Disease and REM Sleep Behavior Disorder in Women
2023
- Randomized phase 2 study of<scp>ACE</scp>‐083, a<scp>muscle‐promoting</scp>agent, in facioscapulohumeral muscular dystrophy
Muscle & Nerve · 2022
- 0813 Post-Pinealectomy Insomnia and Melatonin Therapy
SLEEP · 2022
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
The Lancet Neurology · 2021
- MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis in a Phase IIb/III Study: COMBAT-ALS Study Design
Neurodegenerative Disease Management · 2021
- Acute Respiratory Failure in Neuromuscular Disorders
2021
- A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2020
- SLEEP×6
- Muscle & Nerve×2
- Neurology×2
- Sleep Medicine Clinics×2
- The Lancet Neurology×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile